Shares of Immuneering Corporation (NASDAQ:IMRX) jumped 12.5% in after-hours trading Thursday after the company released updated clinical data for its pancreatic cancer program.
Immuneering reported a median overall survival of 17.3 months in first-line metastatic pancreatic cancer patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel in its Phase 2a trial, based on a data cutoff of April 24, 2026. The expanded analysis covers 55 patients and is scheduled for presentation at the American Society of Clinical Oncology Annual Meeting on June 1, 2026.
The 55-patient expanded cohort consists of an initial group of 34 patients that had been previously reported, together with 21 additional patients added to the analysis. Company materials state that full data to be presented will include details on overall survival, progression-free survival, response rates, safety, weight stability, and other measures. The results will be delivered in an oral presentation by Peter Vu of UC San Diego Health on June 1, 2026.
On the safety front, the trial recorded two categories of treatment-related adverse events at Grade 3 or higher in 10% or more of patients: anemia at 16% and neutropenia at 18%. Immuneering noted that both of these events were chemotherapy-related and that the overall tolerability profile aligns with prior updates.
Separately, Immuneering is advancing its pivotal Phase 3 MAPKeeper 301 trial evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer patients. The company said the Phase 3 study is currently recruiting and that it remains on track to dose the first patient in mid-2026.
Investors and analysts will have an opportunity to hear more directly from the company during a planned investor conference call on June 1, 2026, at 8:00 a.m. EST.
Market reaction - The stock move in after-hours trading followed the release of the updated Phase 2a results.
Next steps - Detailed results will be presented at ASCO on June 1, 2026, and the company continues to recruit patients for its Phase 3 MAPKeeper 301 trial with first dosing anticipated mid-2026.